Traditional PK-PD Indices for Efficacy – Can We Do Better?

Por Lakota, Elizabeth A, Bader, Justin C, Bhavnani, Sujata M, Andes, David R, Ambrose, Paul G
Publicado no Open Forum Infect Dis (2017)

Time for Precision: A World Without Susceptibility Breakpoints

Por Bader, Justin C, Lakota, Elizabeth A, Andes, David R, Rubino, Christopher M, Ambrose, Paul G, Bhavnani, Sujata M
Publicado no Open Forum Infect Dis (2018)

Norepinephrine in Combination with Antibiotic Therapy Increases both the Bacterial Replication Rate and Bactericidal Activity

Por Ambrose, Paul G., VanScoy, Brian D., Adams, John, Fikes, Steven, Bader, Justin C., Bhavnani, Sujata M., Rubino, Christopher M.
Publicado no Antimicrob Agents Chemother (2018)

1389. Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model Against S. aureus (SA) and S....

Por Lepak, Alexander J, Zhao, Miao, Liu, Qingmei, Wang, Ping, Wang, Yanli, Bader, Justin C, Ambrose, Paul G, Andes, David R
Publicado no Open Forum Infect Dis (2018)

1340. Population Pharmacokinetic (PK) Analysis of APX001 Using Phase 1 Data

Por Trang, Michael, Bader, Justin C, Ople, Eric A, Kramer, William G, Hodges, Michael R, Bhavnani, Sujata M, Rubino, Christopher M
Publicado no Open Forum Infect Dis (2018)

Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptoco...

Por Lepak, Alexander J., Zhao, Miao, Liu, Qingmei, Wang, Ping, Wang, Yanli, Bader, Justin C., Ambrose, Paul G., Andes, David R.
Publicado no Antimicrob Agents Chemother (2019)

At the Crossroads of Stewardship and Technology: Impact of Pharmacokinetic-Pharmacodynamic (PK-PD) Integrated Electronic Decision Support Software (EDSS) on the Treatment of Patien...

Por Bader, Justin C, Bulik, Catharine C, Bhavnani, Sujata M, Rubino, Christopher M, Sweeney, Kim L, Ambrose, Paul G, Owens, Robert C
Publicado no Open Forum Infect Dis (2017)

In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model

Por Zhao, Miao, Lepak, Alexander J., VanScoy, Brian, Bader, Justin C., Marchillo, Karen, Vanhecker, Jamie, Ambrose, Paul G., Andes, David R.
Publicado no Antimicrob Agents Chemother (2018)

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata

Por Bader, Justin C., Lakota, Elizabeth A., Flanagan, Shawn, Ong, Voon, Sandison, Taylor, Rubino, Christopher M., Bhavnani, Sujata M., Ambrose, Paul G.
Publicado no Antimicrob Agents Chemother (2018)

Getting it Right the First Time: Relating Pharmacokinetic-Pharmacodynamic Target Attainment and Patient Outcomes

Por Bulik, Catharine C, Bader, Justin C, Lakota, Elizabeth A, Bhavnani, Sujata M, Rubino, Christopher M, Sweeney, Kim L, Ambrose, Paul G, Owens, Robert C
Publicado no Open Forum Infect Dis (2017)

Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial...

Por Bhavnani, Sujata M, Zhang, Li, Hammel, Jeffrey P, Rubino, Christopher M, Bader, Justin C, Sader, Helio S, Gelone, Steven P, Wicha, Wolfgang W, Ambrose, Paul G
Publicado no J Antimicrob Chemother (2019)

Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters

Por Lakota, Elizabeth A., Bader, Justin C., Ong, Voon, Bartizal, Ken, Miesel, Lynn, Andes, David R., Bhavnani, Sujata M., Rubino, Christopher M., Ambrose, Paul G., Lepak, Alexander J.
Publicado no Antimicrob Agents Chemother (2017)